Rodriguez, Martin http://orcid.org/0000-0003-4493-0130
Trevisan, Brady
Ramamurthy, Ritu M. http://orcid.org/0000-0002-7131-6702
George, Sunil K.
Diaz, Jonathan http://orcid.org/0000-0002-3309-0335
Alexander, Jordan
Meares, Diane
Schwahn, Denise J. http://orcid.org/0000-0001-8665-2402
Quilici, David R.
Figueroa, Jorge
Gautreaux, Michael http://orcid.org/0000-0003-3666-7010
Farland, Andrew
Atala, Anthony http://orcid.org/0000-0001-8186-2160
Doering, Christopher B. http://orcid.org/0000-0002-5662-0060
Spencer, H. Trent http://orcid.org/0000-0001-8062-2202
Porada, Christopher D. http://orcid.org/0000-0002-7321-7556
Almeida-Porada, Graça http://orcid.org/0000-0002-6715-865X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL135853, HL148681, HL135853, HL148681)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM103440, GM103440)
Howard Hughes Medical Institute (Gilliam Graduate Fellowship)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (2T32EB014836-06A, 2T32EB014836-06A)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 19 April 2022
Accepted: 26 June 2023
First Online: 14 July 2023
Competing interests
: C.B.D. and H.T.S. are co-founders of Expression Therapeutics, Inc. and own equity in the company. Dr. Denning is an employee of Expression Therapeutics, Inc. Expression Therapeutics licensed the intellectual property associated with the codon optimized ET3 transgene and HCB promoter. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. The rest of the co-authors have no competing financial and non-financial interests.